Table 3.
Characteristics of people initiating PPI treatment between 1 July 2013 and 30 June 2015.
| All people initiating PPI treatment 2013–2015 | Maintenance treatment* | Long-term continuous treatment* | Long-term intermittent treatment* | |
|---|---|---|---|---|
| N (%)† | 1,794,133 (100) | 455,697 (25) | 107,993 (6) | 176,461 (10) |
| Sex (%)‡: | ||||
| Female | 999,266 (56) | 249,164 (55) | 58,497 (54) | 96,874 (55) |
| Male | 794,867 (44) | 206,533 (45) | 49,496 (46) | 79,587 (45) |
| Age at PPI initiation, median (IQR) | 52 (36–65) | 59 (46–71) | 66 (54–77) | 60 (48–70) |
| <18 | 83,331 (5) | 12,775 (3) | 1,179 (1) | 2038 (1) |
| 18–34 | 327,367 (18) | 44,042 (10) | 4,945 (4) | 13419 (8) |
| 35–49 | 413,313 (23) | 83,911 (18) | 13,898 (13) | 31738 (18) |
| 50–64 | 495,860 (28) | 136,322 (30) | 30,028 (28) | 58783 (33) |
| 65–74 | 269,260 (15) | 91,777 (20) | 25,827 (24) | 39277 (22) |
| 75–84 | 145,935 (8) | 57,933 (13) | 20,427 (19) | 22020 (13) |
| 85+ | 59,087 (3) | 28,937 (6) | 11,689 (11) | 9186 (5) |
| Comorbid conditions as identified by the RxRisk algorithm: | ||||
| At least one medicine to treat comorbidity | 1,565,863 (87) | 409,715 (90) | 102,288 (95) | 163,407 (93) |
| Median number of medicines to treat comorbidity (IQR) | 3 (1–4) | 3 (2–5) | 4 (3–6) | 3 (2–5) |
| Select co-administered medicines: | ||||
| Dispensed at least one NSAID during PPI treatment | 516,123 (33) | 166,346 (37) | 35,451 (33) | 83,844 (48) |
| Median (IQR) number of NSAIDs dispensed during PPI treatment | 3 (1–9) | 5 (2–14) | 4 (1–13) | 7 (3–22) |
| Dispensed at least one anticoagulant medicine during PPI treatment | 282,553 (18) | 123,605 (27) | 41,384 (38) | 55,077 (31) |
| Median (IQR) number of anticoagulant medicines dispensed during PPI treatment | 6 (2–22) | 10 (3–30) | 14 (4–27) | 16 (5–49) |
*
Individuals receiving maintenance treatment may have gone to receive long-term treatment. The groups are not mutually exclusive.
†
Percentages are out of all individuals initiating PPI treatment 2013–2015.
‡
Percentages from this point to the end of the table are column percentages (by treatment group).
IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton-pump inhibitor.